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Background: The purpose of this study was to evaluate treatment patterns and outcomes of stereotactic body
radiotherapy (SBRT) for centrally located primary non-small cell lung cancer (NSCLC) or lung metastases from the
RSSearch® Patient Registry, an international, multi-center patient registry dedicated to radiosurgery and SBRT.
Methods: Eligible patients included those with centrally located lung tumors clinically staged T1-T2 N0, M0,
biopsy-confirmed NSCLC or lung metastases treated with SBRT between November 2004 and January 2014. Descriptive
analysis was used to report patient demographics and treatment patterns. Overall survival (OS) and local control
(LC) were determined using Kaplan-Meier method. Toxicity was reported using the Common Terminology Criteria
for Adverse Events version 3.0.
Results: In total, 111 patients with 114 centrally located lung tumors (48 T1-T2,N0,M0 NSCLC and 66 lung metastases)
were treated with SBRT at 19 academic and community-based radiotherapy centers in the US and Germany. Median
follow-up was 17 months (range, 1–72). Median age was 74 years for primary NSCLC patients and 65 years for lung
metastases patients (p < 0.001). SBRT dose varied from 16 – 60 Gy (median 48 Gy) delivered in 1–5 fractions (median
4 fractions). Median dose to centrally located primary NSCLC was 48 Gy compared to 37.5 Gy for lung metastases
(p = 0.0001) and median BED10 was 105.6 Gy for primary NSCLC and 93.6 Gy for lung metastases (p = 0.0005).
Two-year OS for T1N0M0 and T2N0M0 NSCLC was 79 and 32.1 %, respectively (p = 0.009) and 2-year OS for lung
metastases was 49.6 %. Two-year LC was 76.4 and 69.8 % for primary NSCLC and lung metastases, respectively.
Toxicity was low with no Grade 3 or higher acute or late toxicities.
Conclusion: Overall, patients with centrally located primary NSCLC were older and received higher doses of SBRT
than those with lung metastases. Despite these differences, LC and OS was favorable for patients with central lung
tumors treated with SBRT. Reported toxicity was low, although low grade toxicities were observed in patients
where dose tolerances approached or exceeded published guidelines. Prospective studies are needed to further
define the optimal SBRT dose for this cohort of patients.
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Stereotactic body radiotherapy (SBRT) is a treatment op-
tion for Stage I patients who are medically inoperable or
who refuse surgery. SBRT has achieved LC and OS rates
comparable to lobectomy in non-randomized studies in
medically inoperable or elderly patients [1–5]. SBRT can
also achieve high LC and low toxicity in patients with
peripheral lung metastases and limited oligometastatic
disease [6–8]. There is increasing interest in SBRT for
the treatment of centrally located lung lesions and iden-
tifying an optimal efficacious SBRT dose that is safe to
deliver. Early reports of SBRT for the treatment of
centrally located lung tumors indicated high rates of
treatment-related toxicities and treatment-related deaths
[9, 10]. In a Phase II study, Timmerman et al. reported
excessive Grade 3–5 toxicity in patients with centrally
located NSCLC treated with 60 – 66 Gy delivered in 3
fractions [10]. Two-year freedom from severe toxicity
was only 54 % in patients with central tumors compared
to 83 % for patients with peripheral tumors. Song et al.
reported 33 % Grade 3–5 toxicity in patients with cen-
trally located Stage I NSCLC treated with 40 – 60 Gy in
3–4 fractions [9]. Eight of nine patients with tumors
adjacent to the bronchus resulted in bronchial strictures
and secondary loss of lung volume. The close proximity
of normal critical organs including the heart, bronchus,
esophagus and trachea to centrally located lung tumors,
create a challenge of achieving an efficacious SBRT dose
while limiting dose to normal tissues.
In more recent studies, SBRT treatment of centrally
located lung tumors has shown promising results in a sub-
set of patients. In these studies, SBRT doses of 23 – 70 Gy
delivered over 1–10 fractions to central lung tumors re-
sulted in LC rates of 60 – 100 % and OS rates of 12 – 74 %
at 2–3 years [11–19]. Acceptable toxicity profiles were
achieved when strict normal tissue dose constraints were
adhered to, [11, 14, 17] however, some authors report
Grade 3 and higher pulmonary toxicities with some Grade
5 toxicity related to the SBRT treatment [12, 13, 16, 18,
19]. The Radiation Therapy Oncology Group (RTOG)
0813 study was initiated to assess five-fraction SBRT regi-
mens for early-stage, centrally located NSCLC in medically
inoperable patients. The results of this study, however, will
not be available for several more years. In the meantime,
community-based practices and academic centers are treat-
ing patients with centrally located lung tumors with large
variations in SBRT dose and fractionation regimens [20].
Until the optimal SBRT dose/fractionation regimens and
doses to normal tissues for central tumors are determined,
it will be critical for treating centers to combine data
collection efforts to gain clinical evidence to support or
redefine SBRT for centrally located tumors.
The RSSearch® Patient Registry is an international data-
base designed to standardize the collection of screening,treatment and outcome data for patients treated with
radiosurgery and SBRT [21]. RSSearch® currently includes
over 15,000 enrolled patients treated with radiosurgery/
SBRT. Initial analysis of RSSearch® reported lung tumors
as the most common extra-cranial treatment location,
with over 5,500 patients with thoracic lesions treated
with SBRT [21]. The purpose of this study is to report
on treatment management practices, toxicity, OS and
LC of centrally located early-stage NSCLC and lung
metastases from patients enrolled in RSSearch® Patient
Registry, thus representing a real-world setting. Patients
with recurrent lung lesions or prior radiation therapy in
the SBRT-treated area were excluded from the analysis.
Methods
A retrospective analysis of patients with centrally located,
early stage T1-T2N0M0 NSCLC or lung metastases and
enrolled in the RSSearch® Patient Registry (Clinicaltrials.gov
Identifier: NCT01885299) was performed. The RSSearch®
Patient Registry is managed by the Radiosurgery Society®, a
non-profit professional medical society. A description of
the methodology, database design and initial patient and
treatment characteristics of patients enrolled in RSSearch®
has been previously reported [21]. The database is housed
by an independent third-party, AdvertekSM, Inc. (Louisville,
KY) and meets all requirements to comply with the Health
Insurance Portability and Accountability Act (HIPAA) and
Safe Harbor Policy to maintain system security, transmis-
sion of data and patient confidentiality. All centers treating
patients with SBRT clinically are offered and encouraged to
participate in RSSearch®. Participation is voluntary and no
compensation is provided either to patients or participating
centers. Each principal investigator is provided a copy
of the RSSearch® Registry protocol, case report forms,
sample patient informed consent, and web-based train-
ing for data entry and database navigation. Local Insti-
tutional Review Board/Ethics Committee (IRB/EC)
approval is required at all participating centers. In-
formed consent was obtained from all patients, as re-
quired by individual IRB/ECs, prior to the patient’s data
entered into the RSSearch® Registry. The selection of
centers for this study included RSSearch® participating
centers that treated patients with centrally located T1-
T2,N0,M0 NSCLC or lung metastasis with SBRT be-
tween November 2004 to January 2014, with complete
data entry fields for screening, treatment and follow-up
(minimum survival data) for their respective patients.
Central lesions were defined as lesions within 2 cm of
the bronchial tree, trachea, major vessels, esophagus,
heart, pericardium, or brachial plexus. Patients with
recurrent lung lesions or prior radiation therapy in the
SBRT-treated area were excluded from the analysis.
Patients were treated at 18 institutions located in the
US and one center located in Munich, Germany.
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treatment planning criteria and treatment planning was
done per institutional guidelines. All patients were simu-
lated supine, in the treatment position. Planning com-
puted tomography (CT) scans were obtained above and
below the region of interest in expiration, inspiration
and free breathing. One mm slice thickness reconstruc-
tions in the axial plane were transferred to the treatment
planning station. Diagnostic positron emission tomog-
raphy (PET) scan images were routinely used for image
fusion to aid target volume delineation. Target volumes
were delineated by the treating physician (radiation on-
cologist, pulmonologist, or surgeon) using all available
imaging studies, typically including at least CT and PET
scanning. The gross tumor volume (GTV) was generally
used as the clinical target volume (CTV), and a margin
of 3–10 mm was used to delineate the planning target
volume (PTV). All planning was performed using in-
verse planning on the MultiPlan® System (Accuray In-
corporated, Sunnyvale, CA) allowing non-isocentric, and
non-coplanar radiation delivery using either a ray tracing
algorithm or Monte Carlo calculations. All patients were
treated using CyberKnife® Stereotactic Radiosurgery Sys-
tem (Accuray Incorporated, Sunnyvale, CA). Real time
tumor tracking was accomplished using Synchrony® Re-
spiratory Motion Tracking System, which synchronizes
the beam delivery with the motion of the target resulting
from respiration, without the need to interrupt the treat-
ment or move the patient. All patients were treated
according to the respective institutional guidelines. To
compare the effects of various treatment protocols with
different treatment fraction sizes and doses, the biologic-
ally effective dose (BED) was calculated using the linear
quadratic model; as BED =D*(1 + d/α/β) where D is the
total dose, d is the dose per fraction and the α/β ratio
for the tumor was 10 Gy. Normal tissue dose restraints
were reported by the treating institutions and captured
in RSSearch® as the maximum point dose and interquar-
tile range for each structure.
Patient follow-up was performed per institutional
guidelines. All participating centers reported follow-up
clinical and imaging data. Local control was evaluated
independently for each lesion at the participating institu-
tion following a modified RECIST (Response Evaluation
and Criteria in Solid Tumors) criteria. Local progression
was defined as at least a 20 % increase in the size of
lesions and/or appearance of one or more lesions in
target treatment location, LC defined as disappearance
of, decrease in, or no increase in size of the treated le-
sions. An independent audit by a contracted third party
was conducted on 10 % of patients to assess accuracy
and completeness of RSSearch® data. De-identified med-
ical records, including consultation reports, diagnostic
imaging reports, pathology reports, treatment planningand delivery records, follow-up consultation reports and
imaging reports were reviewed and compared to data
recorded in RSSearch®. Any missing information or devi-
ations were immediately reported to the participating
center and corrections were made prior to data analysis.
Analyses of LC, and OS were calculated using the
Kaplan-Meier method. LC was analyzed for each
treated tumor whereas analysis of OS was calculated
for every patient. Specific cause of death was not re-
ported for all patients in RSSearch® and therefore not
evaluated in this study. Subgroups were compared
using X2 and log-rank statistics. Values of p < 0.05 were
considered statistically significant. For primary central
lung tumors significant factors including age, T Stage and
BED, were included in a multivariate Cox regression
model. Statistical calculations were conducted using
GraphPad Prism (La Jolla, CA) and STATA (StatCorp
LP, TX). Toxicity was scored according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events, version 3 (CTCAEv3).
Results
Patient and treatment characteristics
From November 2005 to January 2014, 111 patients with
centrally located early-stage T1-T2N0M0 NSCLC (47
patients) or lung metastases (64 patients) were treated
with SBRT. Table 1 summarizes the patient and tumor
characteristics. Patients with centrally located primary
NSCLC were significantly older than those with lung
metastases (74 years vs 65 years, respectively, p < 0.001).
The median Karnofsky Performance Score (KPS) was
80 % (range 60–100) in both cohorts. Sixty-four percent
of primary NSCLC patients were considered to be surgi-
cally/medically inoperable and 37 % of patients with
lung metastases; the remaining patients refused other
treatment options. The majority of patients with primary
NSCLC (77 %) had no prior treatment, whereas the
majority of patients with lung metastases had received
prior treatments including chemotherapy (68 %), surgery
(26 %), immunotherapy (9 %) and radiofrequency abla-
tion (4 %). Patients that received previous radiation
therapy in the SBRT-treated area were excluded from
this study. Histological confirmation was available for all
primary NSCLC cases, of which 46 % were squamous
cell carcinoma, 48 % NSCLC not otherwise specified,
and 6 % adenocarcinoma. Fifty-six percent were staged
T1N0M0 and 44 % staged T2N0M0. The most common
primary sites for lung metastases were colorectal (30 %),
kidney (15 %), lung (11 %), breast (11 %) and gyne-
cological (11 %) cancer. With respect to the entire
cohort, 46 % of lesions were located near the hilum, two
lesions abutted the aorta, three lesions were adjacent to
the trachea, and two lesions were adjacent to the medi-
astinum. The median lesion volume for all lesions was






Number of Patients 47 64
Age (years) < 0.001
Median 74 65
Range (41 – 93) (35 – 84)
Gender 0.258
Male 28 (60 %) 31 (48 %)
Female 19 (40 %) 33 (52 %)
KPS (%) 0.678
Median 80 80
Range 60 – 100 60 – 100
Prior Treatments
None 36 (77 %) 17 (30 %)
Chemotherapy 8 (17 %) 39 (68 %)
Surgery 3 (6 %) 15 (26 %)
Immunotherapy 0 (0 %) 5 (9 %)
Radiofrequency
Ablation
0 (0 %) 2 (4 %)
Other 2 (4 %) 3 (5 %)
Tumor Volume (cc) 0.117
Median 24.4 20.6
Range (2 – 280) (0.3 – 147)
TNM status (n = 48)
T1N0M0 27 (56 %)
T2N0M0 21 (44 %)
Tumor Histology (n = 48)




NSCLC not specified 23 (48 %)
Table 2 SBRT treatment characteristics
Primary NSCLC Lung Metastases p-value
Number of Lesions 48 66
Prescribed Dose (Gy) 0.0001
Median 48 37.5
Range (20 – 60) (16 – 60)
BED10 (Gy) 0.0005
Median 105.6 93.6
Range 48 – 180 37.5 – 180
Dmax (Gy)
Median 72.7 66.2 0.048
Range (40.5 – 105) (21.7 – 94)
Number of fractions 0.013
Median 4 3
Range 1–5 1–5
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volume of primary NSCLC was 24.4 cc (range 2 –
280 cc) and the median lesion volume of lung metastases
was 20.6 cc (range 0.3 – 147 cc; Table 1).
SBRT treatment dose was 16 – 60 Gy (median 48 Gy)
delivered in 1–5 fractions (median 4 fractions). The median
prescribed dose to centrally located primary NSCLC was
48 Gy (range 20 – 60 Gy) compared to 37.5 Gy (range 16 –
60) for lung metastases (p = 0.0001; Table 2), and the me-
dian number of fractions delivered to primary NSCLC and
lung metastases was 4 and 3, respectively (p = 0.013). Due
to the wide variation in dose/fractionation regimens, BED10
was calculated for each lesion. Overall, patients with pri-
mary NSCLC received higher BED10 compared to patients
with lung metastases (Fig. 1), with a median BED10 of
105.6 Gy for primary NSCLC lesions and 93.6 Gy for meta-
static lesions (p = 0.0001).Overall survival and local control
The median follow-up period was 17 months (range,
1–72 months). Median OS for patients with primary
NSCLC and lung metastases was 26 and 24, months,
respectively (p = 0.78 by log-rank test; Fig. 2a). With
respect to only primary NSCLC patients, median OS
was 37 months for T1 and 16 months for T2 (p =0.009
by log-rank test; Fig. 2b). One-year OS for T1, T2 and
lung metastases was 91.3 % (95 % CI: 69.3 – 97.7),
57.8 % (95 % CI: 32.7 – 75.1) and 77.4 % (95 % CI: 63.4
– 86.6), respectively. Two-year OS for T1, T2 and lung
metastases was 79 % (95 % CI: 52.1 – 91.8), 32.1 %
(95 % CI: 19.0 – 54.2), and 49.6 % (95 % CI: 33.7 – 63.5),
respectively. In univariate analysis of potential prognos-
tic factors for OS, T stage (Wilcoxon-Breslow T1 vs T2
p = 0.0096) and age (continuous log rank p = 0.0105) was
significantly associated with OS. However, these vari-
ables along with the potential interaction of BED10
proved not to be significant in Cox multivariable
analysis.
Lesion response was available for 82 patients and
included 33 primary NSCLC lesions and 49 lung metas-
tases. There were 17 local failures; 6 (12.8 %) primary
NSCLC and 11 (16.6 %) lung metastases (p = 0.54). The
one-year LC rate for primary NSCLC and lung metasta-
ses was 88.6 % (95 % CI: 69.4 – 96.2 %) and 82.9 %
(95 % CI: 63.4 – 95.7 %), respectively (Fig. 3). The two-
year LC rate for primary NSCLC and lung metastases
was 76.4 % (95 % CI: 51.5 – 87.0 %) and 69.8 % (95 %
CI: 48.0 – 83.8 %), respectively. There was no significant
difference for LC between T1 and T2 tumors. In this
cohort, prescription dose and BED10 did not have a
significant effect on LC, with a median BED10 of 100 Gy
(range 37.5 Gy – 151.2 Gy) for patients with local
Fig. 1 Frequency distribution of BED10 for centrally located primary
NSCLC (black) and lung metastases (grey)





















No. Primary 33 19 9 6 3 1 0
No. Mets 49 20 9 6 2 1 1
p = 0.29
Fig. 3 Kaplan-Meier analysis of LC for patients with centrally
located primary NSCLC and lung metastases. Number of subjects
at risk is shown below. Tick marks indicate censored patients
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180 Gy) for those without local failures (p = 0.71). For
central primary lung tumors, age, T stage and dose
(BED) did not have any significant prognostic impact on





























Primary 47 30 17 10 4 2 0















T1 26 19 14 6 3 0
T2 21 11 6 5 3 2 2
p = 0 .0 0 9
A
B
Fig. 2 Kaplan-Meier analysis of overall survival for patients with
centrally located primary NSCLC and lung metastases (a) and for
patients with T1N0M0 and T2N0M0 (b) lesions. Number of subjects
at risk are shown below. Tick marks indicate censored patientsDoses to organs at risk and toxicities
The maximum point dose (Dmax) was reported for
organs at risk and shown as mean Dmax with 95 % CI
and median Dmax (Table 3). The mean Dmax to the
bronchus was 34 Gy (95 % CI: 24 – 44 Gy), mean Dmax
for major vessels was 35 Gy (95 % CI: 31 – 40 Gy), mean
Dmax to the trachea was 24 Gy (95 % CI: 18 – 30 Gy),
the mean Dmax for esophagus was 14 Gy (95 % CI:
11 – 16 Gy), mean Dmax for heart was 22 Gy (95 % CI:
18 – 25 Gy), mean Dmax to the spinal cord was 10 Gy
(8 – 12 Gy) and mean Dmax to skin was 27 Gy (17 –
36 Gy). As a comparison, normal tissue dose con-
straints recommended by the MD Anderson Cancer
Center group for SBRT-treated centrally located lung
tumors are shown in Table 3 [11]. The mean and me-
dian Dmax values for bronchus, major vessels, trachea,
esophagus, heart, spinal cord and skin from patients in the
RSSearch® database met or were below the maximum
point dose constraint recommended by MD Anderson,
although there were a limited number of patients that did
have doses to normal structures that exceeded the
recommendations.
Treatment-related toxicity is shown in Table 4. Fatigue
was the most common toxicity and occurred in 5 pa-
tients. One patient had an acute Grade 2 cough and one
patient had acute Grade 2 pain. One patient had an
acute Grade 1 esophagitis. This patient had a 2.9 cm
metastatic paratracheal lung metastases treated with
35 Gy in 5 fractions and received a maximum point dose
of 40.8 Gy to the esophagus. There were no Grade 3 or
higher acute toxicities. The number of late toxicities re-
ported was low. Two patients had late Grade 2 dyspnea,
one of these patients also had a late Grade 2 cough. This
patient had a 4 cm3 primary NSCLC located adjacent to
the right hilum. The patient was treated with 48 Gy in 4
fractions and received a maximum point dose of 62.9 Gy
Table 3 Maximum point dose to organs at risk
Organ Mean Dmax Median Dmax MDACC [11]
(95 % CI) (range) Dmax Recommendations (50 Gy/4 Fx)
Esophagus 14 Gy (11 – 16) 11 Gy (0 – 51) ≤ 35 Gy
Bronchus 34 Gy (24 – 44) 38 Gy (26 – 75) Bronchial tree:
≤38 Gy
Trachea 24 Gy (18 – 30) 20 Gy (0 – 75) V35 < 1 cm3
Heart 22 Gy (18 – 25) 18 Gy (0.5 – 66) ≤45 Gy
Major vessels 35 Gy (31 – 40) 31 Gy (13–76) ≤56 Gy
Spinal cord 10 Gy (8 – 12) 9 Gy (1 – 24) <25 Gy
Skin 27 Gy (17 – 36) 17 (9 – 73) 30 < 50 cm3
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Grade 2 chest pain and one patient with late Grade 2
pneumonitis. The patient with the Grade 2 pneumonitis
had a 66.8 cm3 metastatic lesion located in the right
peri-hilum region and was treated with 50 Gy in 5 frac-
tions (Dmax 63 Gy). There were no Grade 3 or higher
late toxicities.
Discussion
In the current observational study which included 111
patients with 114 centrally located early-stage NSCLC or
lung metastases, SBRT dose and fractionation regimens
varied considerably across centers with doses ranging
from 16 – 60 Gy (median 48 Gy) delivered in 1 – 5 frac-
tions (median number of 4 fractions). Overall, patients
with primary NSCLC were older and received greater
prescribed dose, Dmax and BED10 compared to lung
metastases. Despite this heterogeneous cohort, we ob-
served OS rates comparable to other published reports
of SBRT for the treatment of centrally located lung
tumors (Table 5). Overall survival rates range from 12 to
74 %, with patients with advanced disease or lungTable 4 Acute and late toxicity following SBRT for centrally
located lung tumors












Pneumonitis 1 1metastases having worse OS compared to those with
Stage I disease [9–17]. Milano et al. reported 2-year OS
for centrally located lung cancer patients with Stage I,
Stage II-III and lung metastases treated with SBRT of
72, 12 and 49 %, respectively [13]. In our study, two-year
OS rates for T1, T2 and lung metastases were 79, 32.1
and 49.6 %, respectively, which is in line with published
reports.
For centrally located lung tumors, LC at 2-years after
SBRT ranges from 60 – 100 % [10–14, 16, 17]. We ob-
served a 2-year LC rate of 76.4 and 69.8 % for primary
NSCLC and lung metastases, respectively, which is com-
parable to results in the literature for this heterogeneous
population. Multiple factors including T stage, tumor
size, and BED10 have been reported as predictors for LC
in other studies of SBRT for central and peripheral lung
tumors [4, 13, 22, 23]. A perplexing finding in our study
however, is that age, T stage and BED10 were not prog-
nostic factors for LC on univariate or multivariate ana-
lysis within our cohort. One potential explanation is
that there were few patients in our study that received
BED10 < 100 Gy and which may impact statistical power.
Other factors that may contribute include the hetero-
geneity of the patients and participating centers. Our
study included 19 centers with patients treated with
SBRT from 2004 to 2014. The experience of the treating
centers and technological advancements have most
likely improved over time and may contribute to factors
that affect statistical considerations.
There are a limited number of multi-center studies
that have reported on clinical outcomes for SBRT treat-
ment for central lung lesions and to our knowledge, this
is one of the largest to date. Schanne et al. recently
reported a multi-center study from Germany and Austria,
which included 90 patients with centrally located Stage
I NSCLC treated with SBRT doses of 24–60 Gy over
1–18 fractions [17]. There was substantial variability in
the prescribed dose across centers, which is similar to
what we observed in our study. In the German/Austrian
study, the median BED10 was 72 Gy, and the 1- and 3-
Table 5 Summary of published studies of SBRT-treated centrally located lung tumors






Timmerman [10] 70 T1-T2,N0M0 NSCLC 60-66 Gy/3 Fx 17.5 2-yr: 95 % 2-yr: 54.7 %
Milano [13] 53 Primary, Metastases 30-63 Gy/2.5-5 Fx 10 2-yr: 73 % 2-yr:
Stage I: 72 %
Stage II-III:12 %
Mets: 49 %
Song [9] 32 Stage I NSCLC 40-60 Gy/3-4 Fx 26.5 2-yr: 85.3 % 1-yr: 70.9 %
2-yr: 38.5 %
Unger [18] 20 Hilar lesions -Primary,
Metastases
30-40 Gy/5 Fx 10 1-yr: 63 % 1-yr: 54 %
Haasbeek [12] 63 Stage I-II NSCLC 60 Gy/8 Fx 35 2-yr: 92.6 % 2-yr: 69 %
5-yr: 92.6 % 5-yr: 49.5 %
Rowe [16] 47 Primary, Metastases BED10: 60–151.2/3-5 Fx 11.3 2-yr: 94 % NA
BED≥ 100 Gy: 100 %
BED < 100 Gy: 80 %
Nuyttens [14] 56 Primary, Metastases 45-60 Gy/5-6 Fx 23 2-yr: 76 % 2-yr: 60 %
BED > 100: 85 % 3-yr: 53 %
BED≤ 100: 60 %
Chang [11] 100 Primary, isolated
recurrences
50 Gy/4 Fx 30.6 3-yr: 96.5 % 3-yr: 70.5 %
70 Gy/5 Fx
Bahig [19] 39 T1-T2N0 NSCLC Median BED10: 113 Gy
(range 106–180 Gy)
22 2-yr: 89 % 2 yr: 74 %
Schanne [17] 90 Stage I/II 24 – 60 Gy/1-18 Fx 18.8 1-yr: 76 % 1-yr: 72 %
2-yr: 64 % 3-yr: 29 %
3-yr: 52 %
Current study 111 T1-T2 NSCLC,
Metastases
20 – 60 Gy/1-5 Fx 17 1-yr: 89 % 2-yr:
2-yr: 72 % T1: 79 %
T2: 32.1 %
Mets: 49.6 %
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respectively. As a comparison, RSSearch® patients with
primary NSCLC received a median BED10 of 105.2 Gy
and 1- and 2-year LC rates were 89.2 and 72.4 %,
respectively. The overall higher BED10 in our study may
be a contributing factor to improved LC compared to
results in Schanne et al.
Escalating SBRT dose can result in improvements in
LC for central lung tumors, however pulmonary toxic-
ities and treatment-related deaths have been reported in
patients where high doses per fractions were given and/
or critical organs at risk (esophagus, heart, great vessels,
brachial plexus) were in the high dose volume region
[9–13, 16, 18, 24, 25]. Unger et al. reported on 20 pa-
tients with hilar lung tumors located next to the main-
stem bronchus treated with 30–40 Gy in 5 fractions
[18]. In this report, one patient with a large GTV
(182 cm3) had an acute Grade 2 esophagitis, where theDmax to the esophagus approached 40 Gy. In our study,
we also observed a patient with a para-tracheal metasta-
sis with Grade 1 esophagitis that received Dmax of
40.8 Gy to the esophagus. The MDACC group has re-
cently revised its recommendation of dose constraints
for normal tissues and recommend a Dmax of ≤ 35 Gy
to the esophagus to limit Grade 2 or higher esophagitis
[11]. Patients with central tumors are at higher risk of
Grade 3 and higher toxicities compared to patients with
peripheral tumors treated with SBRT [26]. The type and
severity of toxicities vary for each individual study. Rowe
et al. reported on 47 patients with central lung lesions
treated mainly with 50 Gy in 4 fractions. In this study,
toxicity was minimal with four patients (9 %) experien-
cing Grade 3dyspnea. There were no Grade 4 toxicities,
however, one patient with a 5.7 cm pulmonary metasta-
sis abutting the left mainstem bronchus suffered a Grade
5 toxicity and died of respiratory failure [16]. Chang
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NSCLC treated with SBRT with 13 % of patients with
Grade 2 chest-wall pain and 1 % of patients with Grade
3 pneumonitis [11]. There were no Grade 4 or higher
toxicities. Overall, reported toxicities in our study were
low compared to other published reports, with no Grade
3 or higher toxicities. A limitation of our study, as with
retrospective studies, is the potential for underreporting.
To address this issue, we did conduct an independent
audit of 10 % of patients to verify data completeness and
accuracy prior to data analysis, however to completely
address the concern of under-reported toxicities, multi-
center prospective studies designed to address toxicity
are needed.
Another unique feature of this study is that all patients
were treated with the CyberKnife® Stereotactic Radiosur-
gery System with Synchrony® Respiratory Tracking Sys-
tem. The CyberKnife with Synchrony Tracking System
uses image-guidance and real-time motion management
to accurately deliver high doses of radiation to tumors
that move with respiration. Studies reporting SBRT
treatment of centrally located tumors using the Cyber-
Knife System have resulted in excellent clinical out-
comes with low incidence of toxicities [14, 18, 19]. A
potential advantage of the CyberKnife System using Syn-
chrony is the capability to track tumor motion, leading
to a reduced margin (typically 3–10 mm) [27–29], in
comparison with linac-based systems that use breath-
hold techniques or respiratory gating, where the tumor
position is generated from different phases of respiration
and typically include an 5–10 mm margin to compensate
for tumor motion with an addition small margin for
set-up uncertainty [13, 30, 31]. This reduction in margin
may spare adjacent normal tissues from receiving high
doses of radiation, thereby resulting in low toxicities.
Future studies need to be done to investigate the long-
term clinical outcomes. In principle SBRT treatments
maximize the delivery of prescribed dose to the tumor
with a rapid fall off of dose to the surrounding normal
tissue. A potential advantage of the CyberKnife System
is it’s intrinsic ability to create a treatment plan which
includes hundreds of non-isocentric beams cumulating
the dose in target volume and minimizing the dose fall
off, thereby sparing organs at risk. Studies have shown
improvements in treatment plan quality when using
non-coplanar beams with sufficient quality and quantity
[32, 33]. Rossi et al. showed that CyberKnife treatment
plans generated with non-coplanar beams were superior
in regards to sparing organs at risk compared to plans
generated with only coplanar beams and that plan qual-
ity improved with increasing number of involved beams
[34]. It is important to note that treatment plan gener-
ation is highly operator dependent and studies assessing
clinical outcomes as a result of CyberKnife treatmentplan optimization for central lung patients have not been
reported. There is also scarcity of literature on the
comparative efficacy and toxicity of various SBRT tech-
niques. Furthermore, future studies need to be done to
assess the effects of SBRT on long-term outcomes on
centrally-located lung tumors.
Patient registries, like RSSearch®, have the ability to
accumulate data from a large number of patients in a
relatively short time and thus, outcomes from patient
registries can be reported years before outcomes of pro-
spective clinical trials. Studies from patient registries will
not replace randomized clinical trials, however outcomes
from patient registries can complement cooperative
group studies as well as generate hypotheses for future
studies. In summary, this observational study it is one of
the largest patient registries to report treatment manage-
ment practices of SBRT for centrally located tumors in a
real world setting. It adds to the increasing body of
evidence for SBRT for centrally located lung tumors and
provides support for future prospective studies to define
the optimal SBRT dose for centrally located lung
tumors.
Conclusions
In this study, patients with centrally located primary
NSCLC and lung metastases were treated with SBRT
doses ranging from 16 – 60 Gy (median 48 Gy) and de-
livered in 1–5 fractions. Overall, patients with primary
NSCLC were older and received higher SBRT doses as
compared to patients with lung metastases. Despite
these differences, we observed excellent LC and OS
rates. Toxicities were low, however, low grade toxicities
were observed in patients with large tumors or where
normal tissues where included in the high dose volume
region. This study contributes to the growing evidence
to support SBRT for the treatment of centrally located
lung tumors, however, prospective studies are needed to
define the optimal SBRT dose/regimens while respecting
normal tissue dose constraints to minimize toxicities.
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